NOLabs

NOLabs was a Swedish biotechnology company specializing in the development of nitric oxide-based therapies for various medical applications. The company focused on leveraging the natural antimicrobial and vasodilatory properties of nitric oxide to treat chronic wounds and skin infections. Their primary technology platform enabled the controlled, localized release of nitric oxide through innovative delivery systems such as patches and gels. The lead product candidate, NitroDerm, was designed specifically for the treatment of diabetic foot ulcers, a major complication of diabetes. In 2012, the company's assets and intellectual property were acquired by Linde Healthcare to enhance their global respiratory and wound care portfolio.